These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 24975809

  • 1. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
    Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall HP, Petri T.
    BMC Pulm Med; 2014 Jun 30; 14():105. PubMed ID: 24975809
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg DJ, Rowe BH, Flores-Figueroa J, Rewerska B, Clark K, Keedy K, Sheets A, Scott D, Horwith G, Das AF, Jamieson B, Fernandes P, Oldach D, SOLITAIRE-ORAL Pneumonia Team.
    Lancet Infect Dis; 2016 Apr 30; 16(4):421-30. PubMed ID: 26852726
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb 30; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
    Sun T, Sun L, Wang R, Ren X, Sui DJ, Pu C, Ren Y, Liu Y, Yang Z, Li F.
    Chin Med J (Engl); 2014 Feb 30; 127(7):1201-5. PubMed ID: 24709166
    [Abstract] [Full Text] [Related]

  • 6. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
    Postma DF, Spitoni C, van Werkhoven CH, van Elden LJR, Oosterheert JJ, Bonten MJM.
    BMC Infect Dis; 2019 Jan 07; 19(1):17. PubMed ID: 30612559
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
    Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S, CAPRIE Study Group.
    Chest; 2005 Nov 07; 128(5):3398-406. PubMed ID: 16304291
    [Abstract] [Full Text] [Related]

  • 8. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
    Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, CAP5 Moxifloxacin Study Group.
    Chest; 2001 Jan 07; 119(1):185-95. PubMed ID: 11157603
    [Abstract] [Full Text] [Related]

  • 9. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD.
    Clin Infect Dis; 2016 Oct 15; 63(8):1007-1016. PubMed ID: 27448679
    [Abstract] [Full Text] [Related]

  • 10. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
    Hoeffken G, Meyer HP, Winter J, Verhoef L, CAP1 Study Group.
    Respir Med; 2001 Jul 01; 95(7):553-64. PubMed ID: 11453311
    [Abstract] [Full Text] [Related]

  • 12. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH.
    Blasi F, Garau J, Medina J, Ávila M, McBride K, Ostermann H, REACH study group.
    Respir Res; 2013 Apr 15; 14(1):44. PubMed ID: 23586347
    [Abstract] [Full Text] [Related]

  • 13. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar 15; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 14. [Analysis of the efficiency of antimicrobial treatment for community-acquired pneumonia in clinical practice].
    Zhukova OV, Ruina OV, Kononova SV, Konyshkina TM.
    Ter Arkh; 2017 Mar 15; 89(8):17-21. PubMed ID: 28914846
    [Abstract] [Full Text] [Related]

  • 15. Delafloxacin: A Review in Community-Acquired Pneumonia.
    Lee A, Lamb YN, Shirley M.
    Drugs; 2022 Jun 15; 82(8):913-923. PubMed ID: 35708893
    [Abstract] [Full Text] [Related]

  • 16. Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
    Rahmel T, Asmussen S, Karlik J, Steinmann J, Adamzik M, Peters J.
    BMC Anesthesiol; 2017 Jun 14; 17(1):78. PubMed ID: 28615012
    [Abstract] [Full Text] [Related]

  • 17. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
    Grossman RF, Hsueh PR, Gillespie SH, Blasi F.
    Int J Infect Dis; 2014 Jan 14; 18():14-21. PubMed ID: 24211230
    [Abstract] [Full Text] [Related]

  • 18. Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study.
    Mahboub B, Al Zaabi A, Al Ali OM, Ahmed R, Niederman MS, El-Bishbishi R.
    BMC Pulm Med; 2015 Sep 30; 15():112. PubMed ID: 26424530
    [Abstract] [Full Text] [Related]

  • 19. Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.
    Belforti RK, Lagu T, Haessler S, Lindenauer PK, Pekow PS, Priya A, Zilberberg MD, Skiest D, Higgins TL, Stefan MS, Rothberg MB.
    Clin Infect Dis; 2016 Jul 01; 63(1):1-9. PubMed ID: 27048748
    [Abstract] [Full Text] [Related]

  • 20. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.